Search results
Results from the WOW.Com Content Network
Erythropoiesis (from Greek 'erythro' meaning "red" and 'poiesis' "to make") is the process which produces red blood cells (erythrocytes), which is the development from erythropoietic stem cell to mature red blood cell. [1] It is stimulated by decreased O 2 in circulation, which is detected by the kidneys, which then secrete the hormone ...
Erythropoiesis-stimulating agents (ESA) are medications which stimulate the bone marrow to make red blood cells. [1] They are used to treat anemia due to end stage kidney disease, chemotherapy, major surgery, or certain treatments in HIV/AIDS. [1] [2] In these situations they decrease the need for blood transfusions. [2]
13857 Ensembl ENSG00000187266 ENSMUSG00000006235 UniProt P19235 P14753 RefSeq (mRNA) NM_000121 NM_010149 RefSeq (protein) NP_000112 NP_034279 Location (UCSC) Chr 19: 11.38 – 11.38 Mb Chr 9: 21.87 – 21.87 Mb PubMed search Wikidata View/Edit Human View/Edit Mouse The erythropoietin receptor (EpoR) is a protein that in humans is encoded by the EPOR gene. EpoR is a 52 kDa peptide with a single ...
Erythropoietin (/ ɪ ˌ r ɪ θ r oʊ ˈ p ɔɪ. ɪ t ɪ n,-r ə-,-p ɔɪ ˈ ɛ t ɪ n,-ˈ iː t ɪ n /; [1] [2] [3] EPO), also known as erythropoetin, haematopoietin, or haemopoietin, is a glycoprotein cytokine secreted mainly by the kidneys in response to cellular hypoxia; it stimulates red blood cell production (erythropoiesis) in the bone marrow.
A Pennsylvania woman faces indecent assault charges after allegedly attempting to ply two tween boys with alcohol and sexually assault one of them after they shoveled snow from her driveway.
The value of U.S. power and utilities deals fell over the last year to $27.8 billion, down by 36% from 2023, as political uncertainty ahead of the Nov. 5 presidential election slowed transactions ...
A "skit" at a fraternity party that left a pledge with burns over 16% of his body led to authorities filing charges against four San Diego State University students, including the person who was ...
Under the trade name Mircera, Roche Pharmaceuticals received approval from the U.S. Food and Drug Administration (FDA) in January 2008 to market a continuous erythropoiesis receptor activator (methoxy polyethylene glycol-epoetin beta) for the treatment of anemia in patients with chronic kidney disease, including in those undergoing dialysis.